Tumors of the Adrenergic System: Imaging and Therapy

  • Cornelis A. Hoefnagel


Neuroendocrine tumors (NET) include pheochromocytoma, neuroblastoma, carcinoid, paraganglioma, chemodectoma, medullary thyroid carcinoma, islet cell tumors, gastrinoma, small cell lung cancer, melanoma, and Merkel cell tumor. NET vary considerably in their clinical presentation, location, and histology but share a common embryonic tissue origin, i.e., the neural crest. In addition, all of these tumors express several unique characteristics that may be exploited in the targeting of radiopharmaceuticals for diagnostic as well as therapeutic purposes [1]. The specific targeting of NET may be achieved via the metabolic route (meta-iodo-benzylguanidine, MIBG), through receptor binding (peptides), or immunologically (antibodies).


Objective Response Rate Medullary Thyroid Carcinoma Islet Cell Tumor Malignant Pheochromocytoma Positron Emission Tomogra 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hoefnagel CA (1994) Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 21:561–581PubMedGoogle Scholar
  2. 2.
    Khafagi FA, Shapiro B, Fig LM et al (1989) Labetalol reduces Iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 30:481–489PubMedGoogle Scholar
  3. 3.
    Reubi JC (1995) Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 36:1825–1835PubMedGoogle Scholar
  4. 4.
    Bardiès M, Bardet S, Faivre-Chauvet A et al (1996) Bispecific antibody and Iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J Nucl Med 37:1853–1859PubMedGoogle Scholar
  5. 5.
    Goldsmith SJ (2009) Update on nuclear medicine imaging of neuroendocrine tumors. Future Oncol 5:75–84CrossRefPubMedGoogle Scholar
  6. 6.
    Troncone L, Rufini V, Montemaggi P et al (1990) The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years experience. Eur J Nucl Med 16:325–335CrossRefPubMedGoogle Scholar
  7. 7.
    Wiseman GA, Pacak K, O’Dorisio MS et al (2009) Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med 50:1448–1454CrossRefPubMedGoogle Scholar
  8. 8.
    Hoefnagel CA, De Kraker J (2004) Pediatric tumors. In: Ell PJ and Gambhir SS (eds) Nuclear medicine in clinical diagnosis and treatment, 3rd edition. Churchill Livingstone, Edinburgh, pp 195–206Google Scholar
  9. 9.
    Leung A, Shapiro B, Hattner R et al (1997) The specificity of radioiodinated MIBG for neural crest tumors in childhood. J Nucl Med 38:1352–1357PubMedGoogle Scholar
  10. 10.
    Vik TA, Pfluger T, Kadota R et al (2009) (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: results from a prospective multicenter trial. Pediatr Blood Cancer 52:784–790CrossRefPubMedGoogle Scholar
  11. 11.
    Yeh SDJ, Larson SM, Burch L et al (1991) Radioimmunodetection of neuroblastoma with Iodine-131-3F8: correlation with biopsy, Iodine-131-Metaiodo ben zylguanidine and standard diagnostic modalities. J Nucl Med 32:769–776PubMedGoogle Scholar
  12. 12.
    Hoefnagel CA, Rutgers M, Buitenhuis CKM et al (2001) A comparison of targetting neuroblastoma with mIBG and anti L1-CAM antibody mAB chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients. Eur J Nucl Med 28:359–368CrossRefPubMedGoogle Scholar
  13. 13.
    Hoefnagel CA, Delprat CC, Zanin D, van der Schoot JB (1988) New radionuclide tracers for the diagnosis and therapy of medullary thyroid carcinoma. Clin Nucl Med 13:159–165CrossRefPubMedGoogle Scholar
  14. 14.
    Hoefnagel CA and Lewington VJ (2004) MIBG therapy. In: Ell PJ and Gambhir SS (eds) Nuclear medicine in clinical diagnosis and treatment, 3rd edn. Churchill Livingstone, Edinburgh, pp 445–457Google Scholar
  15. 15.
    Troncone L, Galli G (1991) Proceedings International Workshop on The Role of [131I]metaiodobenzylguanidine in the Treatment of Neural Crest Tumors. J Nucl Biol Med 35:177–362Google Scholar
  16. 16.
    Baulieu J-L, Guilloteau D, Baulieu F et al (1988) Therapeutic effectiveness of Iodine-131 MIBG metastases of a nonsecreting paraganglioma. J Nucl Med 29:2008–2013PubMedGoogle Scholar
  17. 17.
    Gedik GK, Hoefnagel CA, Bais E, Olmos RA (2008) 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 35:725–733CrossRefPubMedGoogle Scholar
  18. 18.
    Safford SD, Coleman RE, Gockerman JP et al (2003) Iodine-131 metaiodobenzylguanidine as an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134:956–962CrossRefPubMedGoogle Scholar
  19. 19.
    Hoefnagel CA (1999) Nuclear medicine therapy of neuroblastoma. Q J Nucl Med 43:336–343PubMedGoogle Scholar
  20. 20.
    Yanik GA, Levine JE, Matthay KK et al (2002) Pilot study of iodine-131 metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 20:2142–2149CrossRefPubMedGoogle Scholar
  21. 21.
    Voûte PA, van der Kleij AJ, de Kraker J et al (1995) Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV. Eur J Cancer 31A:596–600CrossRefPubMedGoogle Scholar
  22. 22.
    Hoefnagel CA, de Kraker J, Valdés Olmos RA, Voûte PA (1994) 131I-MIBG as a first-line treatment in high-risk neur-oblastoma patients. Nucl Med Commun 15:712–717CrossRefPubMedGoogle Scholar
  23. 23.
    Kraeber-Bodéré F, Bardet S, Hoefnagel CA et al (1999) Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial. Clin Cancer Res 5:3190s–3198sPubMedGoogle Scholar
  24. 24.
    Zuetenhorst H, Taal BG, Boot H et al (1999) Longterm palliation in metastatic carcinoid tumours with various applications of meta-idobenzylguanidine: pharmacological MIBG, 131I-labeled MIBG and the combination. Eur J Gastroenterol Hepatol 11:1157–1164CrossRefPubMedGoogle Scholar
  25. 25.
    Safford SD, Coleman RE, Gockerman JP et al (2004) Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 101:1987–1993CrossRefPubMedGoogle Scholar
  26. 26.
    Taal BG, Hoefnagel CA, Valdés Olmos RA et al (1996) Palliative effect of Metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 14:1829–1838PubMedGoogle Scholar
  27. 27.
    Taal BG, Hoefnagel CA, Boot H et al (2000) Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol 11:1437–1443CrossRefPubMedGoogle Scholar

Copyright information

© Springer Verlag Italia 2010

Authors and Affiliations

  • Cornelis A. Hoefnagel
    • 1
  1. 1.Department of Nuclear MedicineThe Netherlands Cancer InstituteAmsterdamThe Netherlands

Personalised recommendations